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More than half a century ago, reversible protein phosphorylation was linked to mitochondrial metabolism through the
regulation of pyruvate dehydrogenase. Since this discovery, the
number of identiﬁed mitochondrial protein phosphorylation
sites has increased by orders of magnitude, driven largely by
technological advances in mass spectrometry-based phosphoproteomics. However, the majority of these modiﬁcations
remain uncharacterized, rendering their function and relevance unclear. Nonetheless, recent studies have shown that
disruption of resident mitochondrial protein phosphatases
causes substantial metabolic dysfunction across organisms,
suggesting that proper management of mitochondrial phosphorylation is vital for organellar and organismal homeostasis.
While these data suggest that phosphorylation within mitochondria is of critical importance, signiﬁcant gaps remain in
our knowledge of how these modiﬁcations inﬂuence organellar
function. Here, we curate publicly available datasets to map the
extent of protein phosphorylation within mammalian mitochondria and to highlight the known functions of
mitochondrial-resident phosphatases. We further propose
models by which phosphorylation may affect mitochondrial
enzyme activities, protein import and processing, and overall
organellar homeostasis.

Phosphorylation and mitochondrial metabolism
Metabolism must respond to dynamic shifts in nutrient
availability and energy demands. Phosphorylation, being a
rapid and reversible posttranslational modiﬁcation (PTM), is
well suited to calibrate these needs. Indeed, phosphorylation
has long been known to modulate metabolic signaling: the ﬁrst
protein associated with phosphorylation-based regulation was
glycogen phosphorylase (1)—a discovery ﬁrst reported in 1955
by Edwin Krebs and Edmond Fischer that earned them the
1992 Nobel Prize in Physiology and Medicine (2).
Early observations also linked phosphorylation to mitochondria. Albert Lehninger’s group noted in the mid-1940s that
incorporation of radioactive phosphate into rat liver phosphoproteins was dependent upon oxidative phosphorylation (3),
* For correspondence: David J. Pagliarini, pagliarini@wustl.edu.

and Eugene Kennedy and colleagues ﬁrst demonstrated cellular
kinase activity against casein using soluble mitochondrial
extract in 1954 (4). However, the discovery of pyruvate dehydrogenase (PDH) regulation by phosphorylation in 1969 by
Lester Reed’s group (and Otto Wieland shortly thereafter)
ﬁrmly established the role of this PTM in mitochondrial biology
(5, 6).
Since these seminal discoveries, major technological advances in mass spectrometry (MS)-based quantitative phosphoproteomics have uncovered tens of thousands of
phosphorylation sites on proteins across various cell types,
tissues, and organisms (7). By curating many of these datasets,
we found, perhaps surprisingly, that 91% of annotated
mitochondrial proteins have at least one reported phosphorylation site as of March 2021 (Fig. 1A). Furthermore, these
mitochondrial proteins have an average of approximately eight
distinct phosphorylation sites (median = 5, Fig. 1B), demonstrating that this modiﬁcation is highly prevalent across the
mitochondrial proteome.
Are these modiﬁcations broadly meaningful for mitochondrial biology? The answer has remained unclear for some time.
Selecting and biochemically characterizing individual phosphorylation events from these large, complex datasets has
proven challenging, obscuring insight into how these modiﬁcations might directly alter mitochondrial protein function.
Thus, despite their prevalence, less than 5% of these phosphorylated residues are associated with any published investigation (Fig. 1C), and even these few “characterized”
modiﬁcations often lack critical details regarding function,
stoichiometry (i.e., the fraction of phosphorylated relative to
unphosphorylated protein), and regulation across physiological contexts.
By some measures, it is reasonable to assume that these PTMs
are a trivial distraction—biological “noise” captured by instruments with ever-increasing sensitivity. Indeed, systemswide analyses have found that mitochondrial phosphoproteins
typically exhibit low stoichiometry (8). Low-stoichiometry
modiﬁcations need not be nonfunctional on principle; modiﬁcations that activate enzyme function, for example, can substantially alter biological function at low stoichiometry (9). Even
for inhibitory modiﬁcations, the collective accumulation of lowstoichiometry events could decrease organellar function, as has
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Figure 1. Phosphorylation is prevalent on mitochondrial proteins. A, of the 1136 proteins identiﬁed in MitoCarta 3.0, 1038 have at least one experimentally determined phosphoisoform, while 98 have no reported phosphoisoforms per PhosphoSitePlus as of March 2021 (7). B, histogram analysis
showing the number of phosphoisoforms identiﬁed per mitochondrial proteins; the median number of phosphoisoforms is shown with a dotted line. C.
Graphical representation of all experimental identiﬁcations of mitochondrial phosphorylation events (8105) versus those with an annotated function (per
the PhosphoSite Plus website). Notably, there is only 4.5% of overlap.

been shown for mitochondrial protein acylation modiﬁcations
(10, 11). Nonetheless, it is reasonable to assume that lowstoichiometry modiﬁcations are less likely to have biological
impact and may reﬂect spurious events.
However, other observations suggest that these PTMs may
possess important regulatory value. For example, multiple
studies have found that phosphorylation sites on mitochondrial proteins are reproducibly dynamic across physiological
states and models of disease (12–15), implying functionality
(or, at least, nonrandomness). Moreover, the select examples
of puriﬁed mitochondrial phosphoproteins or phosphomimetics show that these PTMs certainly can alter protein activity when present (albeit, often at stoichiometry higher than
what was observed in cells or tissues). Collectively, these observations demand better answers to two fundamental questions: are phosphorylation sites on mitochondrial proteins
functionally meaningful? If so, which?

Mitochondria-resident phosphatases
In debating the answers to the questions above, we were
struck by another key data point: mitochondria appear to
possess a set of resident protein phosphatases. The MitoCarta
compendia have included 12 candidate protein phosphatases
(16–18) (Fig. 2A), many of which are conserved across
eukaryotic species, suggesting ancient origins for mitochondrial dephosphorylation (19) (Fig. 2B). The presence of 12
mitochondrial phosphatases in a single organelle may, at ﬁrst
glance, imply substantial functional redundancy, but evidence
suggests that these proteins have distinct, nonoverlapping
roles. First, mitochondrial phosphatases exploit ﬁve distinct
catalytic domains, each with speciﬁc residue preferences that
confer substrate selectivity (Fig. 2C). Furthermore, these
phosphatases are subcompartmentalized across the organelle
(20–22), physically dividing substrate pools and functions.
RNA-seq proﬁles of many mitochondrial phosphatases show
tissue-speciﬁc expression (23), further diversifying functions
in vivo (Fig. 2D). Finally, genetic or pharmacological perturbation of many mitochondrial phosphatases results in distinct
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—and often severe—phenotypes, suggesting that these enzymes enable mitochondrial homeostasis through unique
functions.
Given these insights, our approach to addressing the
questions above has been to proﬁle the mitochondrial
phosphoproteome following the perturbation of one of these
phosphatases (24–26). This approach can begin to resolve
two fundamental challenges to understanding the mitochondrial phosphorylation network. First, these experiments
identify phosphorylation sites that change in occupancy,
suggesting functional relevance. This is a much needed
prioritization metric for transitioning from high-throughput
datasets to mechanistic investigations. Second, these studies
place mitochondrial phosphatases within a biological
framework, illuminating both the function of the phosphatase itself and the pathways dynamically inﬂuenced by
phosphorylation. Beyond these biological insights, the study
of phosphatase knockout systems offers a technical strength
in providing a gain-of-signal readout (i.e., elevated phosphorylation levels), which can be detected and quantiﬁed
more accurately than loss-of-signal approaches. Finally,
recent compendia of mitochondrial proteins include more
candidate protein phosphatases than protein kinases, suggesting that perturbation of these genes provides a more
straightforward strategy for illuminating the mitochondrial
phosphoproteome. This strategy has recently highlighted
surprising and unexpected insights into the inﬂuence of
mitochondrial phosphorylation on organellar function and
metabolic homeostasis.

Knockout models of mitochondrial phosphatases
highlight critical organellar functions
Genetic knockout models have been characterized for four
mitochondrial phosphatases in yeast (24, 25, 27), and four in
mice—Pdp1, Ppm1k, Pgam5, and Pptc7. Knockout models of
phosphatases classically associated with metabolism, such as
Pdp1 and Ppm1k, are viable and have phenotypes that likely
derive from their annotated functions, including altered blood
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Figure 2. Mitochondrial phosphatases identiﬁed across organisms. A and B, twelve phosphatases localize to mitochondria in mice and humans (A) and
ﬁve reside in mitochondria in Sacchraomyces cerevisiae (B). Phosphatases are color-coded according to their phosphatase domain as deﬁned in panel C.
Sublocalization of mitochondrial phosphatases is denoted as follows: matrix localized = circle, inner mitochondrial membrane proteins = triangle, intermembrane space proteins = cross, outer membrane proteins = square, and dual-localized proteins, or proteins with unknown localization = star. C, proteins
contain PP2C (red), DUSP (orange), HAD (blue) HP (dark green), and PTP (light green) phosphatase domains in mammalian mitochondria. D, gene expression
data of mitochondrial phosphatases, represented as a heat map of median transcripts per million (TPM) as reported in the GTEx database (23). The heat map
includes all ranges within 100 TPM, except for DUSP26, which has median TPM values of 104 for cerebellum and 193 for skeletal muscle. Gray boxes indicate
transcripts were not quantiﬁed.

glucose levels for Pdp1−/− mice and elevated circulating
branched chain amino acids for Ppm1k−/− mice (28, 29).
Knockout of Pgam5 leads to multiple phenotypes, including a
Parkinson’s-like movement disorder and T cell dysfunction
(30, 31). Notably, global phosphoproteomic analysis has not
been performed on these models, suggesting that the full
breadth of substrates and pathways affected by loss of these
phosphatases is not yet known.
We recently generated a global knockout mouse of the
matrix-localized phosphatase Pptc7 (26). Strikingly, the loss of
Pptc7 manifests in severe metabolic abnormalities, including
hypoketotic hypoglycemia, leading to fully penetrant perinatal
lethality within one day of birth. On a cellular level, loss of the
phosphatase markedly diminished mitochondrial content,
suggesting that dephosphorylation of mitochondrial proteins is
somehow critical for maintaining a healthy mitochondrial
population. While the biochemical details of how this occurs
are not fully worked out, these data demonstrate that proper
management of mitochondrial phosphorylation is essential for
mammalian development and, we propose, is of far greater
importance to the biology of this organelle than is currently
appreciated.

The considerable phenotypes exhibited by the four mitochondrial phosphatase knockout models demonstrate that at
least a portion of observed mitochondrial phosphorylation
sites hold functional relevance and cannot be attributed to
mere technical artifacts. These observations also add important context to the issue of low phosphosite stoichiometry
noted above. First, the reason that mitochondrial phosphosites
exhibit low stoichiometry may be that mitochondrial phosphatases constitutively keep them that way. In our study, the
loss of a mitochondrial phosphatase caused elevated stoichiometry at select phosphorylation sites, which subsequently led
to impaired organellar function. This is consistent with the
handful of mitochondrial phosphosites studied in vitro, most
of which were inhibitory to protein function. Second, these
data suggest that performing phosphoproteomic proﬁling
under physiological conditions whereby the expression of a
select phosphatase is low (e.g., altered nutrient conditions or
elevated stress) could yield very different (i.e., elevated) protein
stoichiometry.
Moving forward, it is essential that we continue to progress
from large-scale proﬁling to mechanistic investigations of individual phosphorylation events. It is important to note that in
J. Biol. Chem. (2021) 297(1) 100880
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mitochondrial phosphatase knockout models, we currently do
not understand whether the observed phenotypes result from
one/a select handful of phosphorylation events, or if the
broader accumulation of phosphorylation on mitochondrial
proteins is somehow collectively detrimental. Relatedly, recent
work has shown that matrix-localized phosphorylation promotes selective mitophagy or turnover of mitochondrial proteins (32), suggesting that the primary effects of
phosphorylation might not lie at the level of individual protein
activity. Further investigations into the mechanisms by which
dysregulated phosphorylation disrupts mitochondrial function
should be an area of active focus in the future.

Where are the kinases?
The severe phenotypes of mismanaged protein phosphorylation in knockout models of protein phosphatases naturally
lead to a second question: How do mitochondrial proteins
become phosphorylated? Multiple studies have identiﬁed kinases such as PKA that translocate to mitochondria and have
even proposed a complete mitochondria-speciﬁc signaling
system comprising G-protein-coupled receptors and cAMP
production (33–36). However, the conditions under which
PKA translocates into mitochondria are not fully worked out,
with some studies suggesting that PKA is not present in the
matrix of select cell types, but instead is only on the outer
mitochondrial membrane bound to an A-kinase anchoring
protein (AKAP) (36). Furthermore, if G-protein-coupled
receptor-mediated PKA activation does occur in the mitochondrial matrix, the signals that selectively activate these
intraorganellar pathways, as well as those that resolve such
signals, are not fully understood. Beyond PKA, other predominantly nonmitochondrial kinases, such as Src family
members, Aurora kinase, and EGFR, have been partially
localized to inner mitochondrial compartments (37–39).
However, similar to PKA, the mechanisms by which they
translocate, the signals prompting this translocation, and the
systems underlying their organellar-speciﬁc regulation are not
known.
Alternatively, it is possible that protein kinases long known
to be resident in the mitochondrial matrix, such as the PDH
kinases (PDKs) and the branched chain amino acid dehydrogenase (BCKDH) kinase (BCKDK), have broader substrate
proﬁles than currently appreciated. These kinases are classically thought to have limited protein kinase activity across the
mitochondrion due to their physical association with their
respective dehydrogenase complexes (5, 40, 41). To our
knowledge, this assumption has not been thoroughly tested,
and some observations suggest that the PDKs and BCKDK
may have a more diverse substrate pool than PDH and
BCKDH. First, proximity labeling studies have shown at least
three PDK isoforms with non-PDH interactors (42), challenging the notion that the PDKs are sequestered to the PDH
complex. Second, treatment of porcine heart mitochondria
with the pan-PDK inhibitor dichloroacetate and pyruvate
diminished 32P-incorporation into multiple unidentiﬁed proteins, consistent with a model in which PDK isoforms phosphorylate proteins beyond PDH (43). Finally, recent work
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identiﬁed an unexpected role for BCKDK in the phosphorylation and regulation of ACLY—a cytosolic enzyme involved
in fatty acid synthesis (44). Thus, noncanonical roles for
the PDKs and BCKDK—both within and outside of mitochondria—seem likely and may inﬂuence mitochondrial
phosphorylation proﬁles more than currently appreciated.
A third possibility invokes the action of resident atypical or
metabolic kinases in phosphorylating mitochondrial proteins.
Mammalian mitochondria contain ﬁve atypical “ADCK” kinases, which are members of the protein kinase-like (PKL)
superfamily (45). Early on, one of these proteins (Coq8 in
Saccharomyces cerevisiae) was linked to coenzyme Q biosynthesis and was postulated to directly phosphorylate proteins
within the coenzyme Q pathway (46). However, structural
analysis revealed that ADCK proteins possess multiple features
poised to inhibit protein kinase activity, including an N-terminal domain that occupies the typical substrate-binding
pocket (45, 47). Recent studies suggest that ADCKs more
likely function as ATPases (48), although Coq8 and its
mammalian orthologs are the only ADCKs that have been
tested rigorously in vitro and in vivo. Beyond the ADCKs, 24
other small-molecule kinases reside within mitochondria that
phosphorylate nucleotides (e.g., the adenylate kinases AK2-4),
lipids (e.g., sphingosine kinase, SPHK2), metabolites (e.g.,
phosphoenolcarboxykinase 2, PCK2), or unknown substrate
classes (e.g., ACAD10 and ACAD11). Emerging evidence
suggests that metabolic kinases may moonlight as protein kinases (49), and thus careful biochemical studies are needed to
determine whether these kinases may contribute to mitochondrial protein phosphorylation.
A ﬁnal model posits that resident mitochondrial protein
kinases are not needed at all. In our Pptc7 work, we identiﬁed elevated occupancy on phosphorylation sites at or within
the mitochondrial targeting sequence (MTS) of multiple
precursor proteins (26). The MTS—a short, N-terminal
segment found on many mitochondrial precursors—is
removed upon entry to the organelle and is thus unlikely to
inﬂuence mature protein function. Despite this, more than
40% of MTS-containing mitochondrial proteins are phosphorylated within or proximal to this sequence (Fig. 3).
These data suggest that phosphorylation may occur by
cytosolic kinases prior to protein import and thus may inﬂuence the mitochondrial import and/or processing of precursor proteins. If phosphorylated mitochondrial precursors
can be imported into mitochondria (as, it seems, they can in
plastids (50)), this phenomenon might extend to much of the
observed mitochondrial phosphoproteome. This mechanism
would allow cross-compartmental regulation of mitochondrial phosphorylation, as cytosolic kinases, activated in
response to various cellular cues, could phosphorylate
mitochondrial precursors to affect their organellar targeting
and function. This could provide a rapid and reversible
mechanism to enrich speciﬁc molecular targets within
mitochondria under dynamic cellular conditions. Furthermore, this mechanism could explain two current mysteries in
the ﬁeld of mitochondrial phosphorylation: (1) the paucity of
mitochondrial-localized kinases relative to mitochondrial

ASBMB AWARD ARTICLE: Highlighting protein phosphorylation in mitochondria

B
p-site within
or at cleaved
N-terminus
(193)
no p-site in
cleaved N-term
(244)

120

Number of proteins

A

100

Total protein
Phosphoprotein

80
60
40
20

90
10
0
11
0
12
0
13
0
14
0
15
0
16
0
17
0
18
0
19
0
20
0

80

60
70

50

40

30

20

10

0

437 N-terminally processed
MitoCarta proteins

Length of cleaved N-terminus (amino acids)

Figure 3. Numerous mitochondrial proteins are phosphorylated near their N-termini. A, N-terminal cleavage sites that likely reﬂect a mitochondrial
targeting sequence (MTS) were determined for 437 proteins. Of these, 193, or 44.2%, are phosphorylated within or proximal to their N-terminal cleaved
region. B, distribution of lengths of cleaved N-termini of 437 proteins, binned by ten amino acid groups (e.g., 1–10 amino acids). Gray bars reﬂect distribution
of all 437 proteins by cleaved N-terminal length, blue bars reﬂect distribution of proteins phosphorylated within their cleaved N-terminus.

phosphatases, and (2) at least for MTS phosphorylation, the
low stoichiometry, because they are inherently transient and
resolved after import.

Future directions and conclusions
The past decade has brought forth an incredible surge in the
quality and quantity of phosphoproteomic studies. These
studies, which span cellular and animal models, have revealed
the unexpected prevalence of phosphorylation on mitochondrial proteins. However, questions remain regarding which of
these modiﬁcations inﬂuence organellar function and the
physiological conditions under which proteins become phosphorylated within the organelle.
Important next steps in understanding the systems-wide
effects of phosphorylation in mitochondria include proﬁling
the functions of mitochondrial phosphatases to understand
not only their substrates and molecular functions but also how
these translate into physiological dysfunction across organisms. Of the 12 known mitochondrial phosphatases, six (i.e.,
Cecr5, Dusp18, Dusp21, Dusp26, Cdc25c, and Ptpn4) have no
known substrates within mitochondria. We propose that a
concerted effort to proﬁle phosphatase knockout models with
quantitative phosphoproteomic and metabolomic techniques
will be key to establishing clear phosphatase–substrate relationships and for prioritizing biologically relevant modiﬁcations that affect mitochondrial processes. Furthermore,
understanding the contexts under which mitochondrial
phosphatases are regulated will elucidate a broader mitochondrial signaling network and help clarify how dynamic
phosphorylation coordinates organellar function.
Finally, understanding mitochondrial phosphorylation may
lead to new therapeutic options for elevating mitochondrial
metabolism. Recent studies have already shown that kinase
inhibition can alleviate mitochondrial dysfunction in mouse
models of mitochondrial disease by dampening mTOR, PKC,
or AMPK signaling (51–53). While it remains unclear how and
to what extent the mitochondrial phosphoproteome is affected
in each of these studies, these data collectively suggest that
protein phosphorylation critically regulates mitochondrial
function and may have therapeutic implications if properly
exploited.

Mounting data suggest that reversible phosphorylation may
be a widespread and underappreciated means of regulation
within mitochondria and that its mismanagement could be an
important underlying feature of mitochondrial pathophysiology. Rigorous new efforts to understand which mitochondrial proteins are affected by phosphorylation, to establish
mechanistically how it alters their function, and to identify the
enzymes that manage these modiﬁcations could motivate a
powerful new therapeutic strategy: the control of mitochondrial metabolism via manipulation of intraorganellar phosphorylation networks.
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